Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from March 5, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on June 3, 2026.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$37.50 – $39.00Entry zone — fair-value band

$38.60Published — price the day we called it

$44.00Target — the price the thesis aimed for

$47.79Peak — highest point inside the window, not a realized return

$42.00Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 57 days.

Peak price

$47.79

peak on May 11, 2026 — not a realized return

Peak gain

+23.8%

peak, from the publication price

Window close

$42.00

end-of-window price, context only

Days to target

Window

March 5, 2026 – June 3, 2026

The thesis — published March 5, 2026

Predicted growth

+14%

over the measurement window

Target price

$44.00

the price the thesis aimed for

Entry zone

$37.50 – $39.00

the fair-value band we waited for

Price at publication

$38.60

published March 5, 2026

Confidence

67%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk makes medicines for diabetes and obesity. Demand for its newer GLP-1 treatments is high, employers are expanding access, and early oral drug results look promising across the industry. Actions against unregulated alternatives could help big brands. The stock has pulled back, creating a possible buying window, though policy and pricing headlines could cause volatility.

Primary drivers

Strong and lasting demand for GLP-1 medicines
Rules against unregulated alternatives can favor big brands
Price dip gives a clearer, less risky buying window
Main risk is policy and pricing headlines affecting sales

How it played out

NVO: target reached in 57 days

Lyra published NVO on 2026-03-05 at 38.60 with a short-term thesis for 14% growth and a 44 target. The thesis pointed to strong GLP-1 demand, rules against unregulated alternatives, a price dip that created a buying window, and policy or pricing headlines as the main risk.

Inside the window, NVO rose to 47.79 on 2026-05-11. That peak was above the 44 target, with a listed peak gain of 23.8%. The target was reached in 57 days. By 2026-06-03, the stock ended at 42. The thesis played out during the window, even though the close was below the peak.

What happened during the window

On 2026-05-06, Novo Nordisk reported first-quarter results and raised its full-year guidance while still expecting sales to fall. The report said Wegovy pill prescriptions had passed 2 million since its January launch. On 2026-03-24, the FDA approval of a higher-dose Wegovy injection was reported.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals